VACBF NYKODE THERAPEUTICS AS Forecast, Technical & Fundamental Analysis

VACBF's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for VACBF moved out of overbought territory on September 17, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 3 instances where the indicator moved out of the overbought zone. In of the 3 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on VACBF as a result. In of 11 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for VACBF turned negative on September 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at .

Bullish Trend Analysis

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.636) is normal, around the industry mean (19.714). P/E Ratio (0.000) is within average values for comparable stocks, (54.201). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.145). VACBF's Dividend Yield (0.498) is considerably higher than the industry average of (0.044). P/S Ratio (8.937) is also within normal values, averaging (346.197).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. VACBF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VACBF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.